REFERENCES
- Chan C C, Buggage R R, Nussenblatt R B. Intraocular lymphoma. Curr Opin Ophthalmol 2002; 13: 411–418, [INFOTRIEVE], [CSA]
- Deangelis L M, Hormigo A. Treatment of primary central nervous system lymphoma. Semin Oncol 2004; 31: 684–692, [INFOTRIEVE], [CROSSREF], [CSA]
- Corn B W, Marcus S M, Topham A, Hauck W, Curran W J, JR. Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000?. Cancer 1997; 79: 2409–2413, [INFOTRIEVE], [CROSSREF], [CSA]
- Behin A, Hoang-Xuan K, Carpentier A F, Delattre J Y. Primary brain tumours in adults. Lancet 2003; 316: 323–331, [CROSSREF], [CSA]
- Cote T R, Manns A, Hardy C R, Yellin F J, Hartge P. Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group. J Natl Cancer Inst 1996; 88: 675–679, [INFOTRIEVE], [CSA]
- Bataille B, Delwail V, Menet E, Vandermarcq P, Ingrand P, Wager M, et al. Primary intracerebral malignant lymphoma: Report of 248 cases. J Neurosurg 2000; 92: 261–266, [INFOTRIEVE], [CSA]
- Chan C C, Wallace D J. Intraocular lymphoma: update on diagnosis and management. Cancer Control 2004; 11: 285–295, [INFOTRIEVE], [CSA]
- Buggage R R, Chan C C, Nussenblatt R B. Ocular manifestations of central nervous system lymphoma. Curr Opin Oncol 2001; 13: 137–142, [INFOTRIEVE], [CROSSREF], [CSA]
- Wolf L A, Reed G F, Buggage R R, Nussenblatt R B, Chan C C. Levels of IL-10 and IL-6 in the vitreous are helpful for differentiation of primary intraocular lymphoma and ocular inflammation. Ophthalmology 2003; 110: 1671–1672, [INFOTRIEVE], [CROSSREF], [CSA]
- de Smet M. D., Stark-Vancs V, Kohler D R, Smith J, Wittes R, Nussenblatt R B. Intraocular levels of methotrexate after intravenous administration. Am J Ophthalmol 1996; 121: 442–444, [INFOTRIEVE], [CSA]
- Smith J R, Rosenbaum J T, Wilson D J, Doolittle N D, Doolittle N D, Siegal T, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002; 109: 1709–1716, [INFOTRIEVE], [CROSSREF], [CSA]
- Hormigo A, Abrey L, Heinemann M H, Deangelis L M. Ocular presentation of primary central nervous system lymphoma: Diagnosis and treatment. Br J Haemotol 2004; 126: 202–208, [CROSSREF], [CSA]
- Alizadeh A A, Eisen M B, Davis R E, Ma C, Lossos I S, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rosenwald A, Wright G, Chan W C, Connors J M, Campo E, Fisher R I, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne R D, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851–862, [INFOTRIEVE], [CROSSREF], [CSA]
- Hegde U, Filie A, Little R F, Janik J E, Grant N, Steinberg S M, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: The role of flow cytometry versus cytology. Blood 2005; 105: 496–502, [INFOTRIEVE], [CROSSREF], [CSA]
- Gutierrez M, Chabner B A, Pearson D, Steinberg S M, Jaffe E S, Cheson B D, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 2000; 18: 3633–3642, [INFOTRIEVE], [CSA]
- Abrey L E, Batchelor T T, Ferreri A J, Gospodarowicz M, Pulczynski E J, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005; 23: 5034–5043, [INFOTRIEVE], [CROSSREF], [CSA]
- Gleissner B, Siehl J, Korfel A, Reinhardt R, Thiel E. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology 2002; 58: 390–396, [PUBMED], [INFOTRIEVE], [CSA]
- Davis J L, Solomon D, Nussenblatt R B, Palestine A G, Chan C C. Immunocytochemical staining of vitreous cells. Indications, techniques, and results. Ophthalmology 1992; 99: 250–256, [INFOTRIEVE], [CSA]
- Whitcup S M, Stark-Vancs V, Wittes R E, Solomon D, Podgor M J, Nussenblatt R B, et al. Association of interleukin-10 in the vitreous and cerebral spinal fluid and primary central nervous system lymphoma. Arch Ophthalmol 1997; 115: 1157–1160, [INFOTRIEVE], [CSA]
- Deckert-Schluter M, Rang A, Wiestler O D. Apoptosis and apoptosis-related gene products in primary non-Hodgkin's lymphoma of the central nervous system. Acta Neuropathol. (Berl) 1998; 96: 157–162, [CROSSREF], [CSA]
- Wilson W H, Teruya-Feldstein J, Fest T, Harris C, Steinberg S M, Jaffe E S, et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 1997; 89: 601–609, [INFOTRIEVE], [CSA]
- Wilson W H, Grossbard M L, Pittaluga S, Cole D, Pearson D, Drbohlav N, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: A pharmacodynamic approach with high efficacy. Blood 2002; 99: 2685–2693, [INFOTRIEVE], [CROSSREF], [CSA]
- Schlegel U, Schmidt-Wolf I G, Deckert M. Primary CNS lymphoma: Clinical presentation, pathological classification, molecular pathogenesis and treatment. J Neurol Sci 2000; 181: 1–12, [INFOTRIEVE], [CROSSREF], [CSA]
- Wilson W H, Dunleavy K, Pittaluga S, Grant N, Steinberg S, Raffeld M, et al. Dose-adjusted EPOCH-rituximab is highly effective in the GCB and ABC subtypes of untreated diffuse large B-cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2004; 104, abstract 159[CSA]
- Pels H, Schmidt-Wolf I G, Glasmacher A, Schulz H, Engert A, Diehl V, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003; 21: 4489–4495, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Doolittle N D, Abrey L E, Bleyer W A, Brem S, Davis T P, Dore-Duffy P, et al. New frontiers in translational research in neuro-oncology and the blood-brain barrier: Report of the Tenth Annual Blood-Brain Barrier Disruption Consortium Meeting. Clin Cancer Res 2005; 11: 421–428, [INFOTRIEVE], [CSA]
- Moreton P, Morgan G J, Gilson D, Smith G M, McVerry B A, Davies J M, et al. The development of targeted chemotherapy for CNS lymphoma-a pilot study of the IDARAM regimen. Cancer Chemother Pharmacol 2004; 53: 324–328, [INFOTRIEVE], [CROSSREF], [CSA]
- Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117–4126, [INFOTRIEVE], [CROSSREF], [CSA]
- Rubenstein J L, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, et al. Rituximab therapy for CNS lymphomas: Targeting the leptomeningeal compartment. Blood 2003; 101: 466–468, [INFOTRIEVE], [CROSSREF], [CSA]
- Kikuchi A, Kawada H, Iwaki Y, Machida S, Tsuchiya T, Fukuda R, et al. [Measurement of rituximab concentration in the cerebrospinal fluid in CNS lymphoma]. Rinsho Ketsueki 2004; 45: 1255–1257, [INFOTRIEVE], [CSA]
- Pels H, Schulz H, Schlegel U, Engert A. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: Experience with two cases and review of the literature. Onkologie 2003; 26: 351–354, [INFOTRIEVE], [CROSSREF], [CSA]
- Schulz H, Pels H, Schmidt-Wolf I, Zeelen U, Germing U, Engert A. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 2004; 89: 753–754, [INFOTRIEVE], [CSA]
- Wong E T, Tishler R, Barron L, Wu J K. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 2004; 101: 139–145, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]